Search
Search Results
##search.searchResults.foundPlural##
-
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1187PDF: 607HTML: 6804 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2318PDF: 1340HTML: 17093Bassan Fig.1: 146Bassan Fig.2: 159Bassan Fig.4: 142Fig.3: 196 -
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1661PDF: 1250HTML: 265 -
SYSTEMIC MASTOCYTOSIS: MULTIDISCIPLINARY APPROACH Systemic Mastocytosis
1578PDF: 1042HTML: 238 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2169PDF: 1721HTML: 383 -
HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS
2042PDF: 768HTML: 3117 -
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA CAR T Cells and Myeloma Treatment
1756PDF: 854HTML: 152 -
CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION
4837PDF: 1795HTML: 2723Untitled: 227 -
TREATMENT OF INDOLENT AND ADVANCED SYSTEMIC MASTOCYTOSIS Systemic Mastocytosis Treatment
2138PDF: 1552HTML: 509 -
Focusing On A Unique Innate Memory Cell Population Of Natural Killer Cells In The Fight Against COVID-19: Harnessing The Ubiquity Of Cytomegalovirus Exposure Memory Cell Population Of Natural Killer Cells in COVID-19 and Cytomegalovirus Exposure
1206PDF: 928HTML: 291 -
THE ROLE OF SLC22A4 IN ACUTE MYELOID LEUKEMIA
499PDF: 253HTML: 79 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2614PDF: 874HTML: 17571Fig1 Caligaris: 181Fig.2 Caliga: 216 -
REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2350PDF: 1001HTML: 7629Untitled: 283Fig2: 186Fig3: 174Fig4: 184 -
Is laboratory monitoring useful in DOACs management?
852PDF: 816HTML: 111 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1657PDF: 1105HTML: 127 -
CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES CAR-T CELL FOR T-CELL MALIGNANCIES
2223PDF: 2056HTML: 199 -
NOVEL DRUGS IN FOLLICULAR LYMPHOMA
4355PDF: 1522HTML: 1555Untitled: 239 -
APLASTIC ANEMIA AND VIRAL HEPATITIS
1277PDF: 531HTML: 23089 -
TOXICITIES ASSOCIATED WITH CAR-T CELL THERAPIES CAR-T Cell Toxicity
2296PDF: 1641HTML: 276 -
CAR-T CELL THERAPY IN B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CAR-T CELL and B-ALL
4308PDF: 3550HTML: 220 -
THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.
4092PDF: 1159HTML: 1962Fig.1: 219Fig. 2: 113Table 1: 204Table2: 225Table 3: 203 -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
4386PDF: 1773HTML: 1111 -
REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy
1602PDF: 625HTML: 214 -
CAR-T CELL THERAPY FOR FOLLICULAR LYMPHOMAS CAR-T and Follicular Lymphoma
2346PDF: 1860HTML: 149 -
ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
2056PDF: 815HTML: 1052 -
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT
1349HTML: 328PDF: 958Suppl. Files: 469 -
PLASMACELL NEOPLASMS WITH SPREADING IN THE BLOOD AND TISSUES: EXTRAMEDULLARY MYELOMA DISEASE A RARE AGGRESSIVE FORM OF MULTIPLE MYELOMA (First of two parts) Extra Medullary Myeloma
2488HTML: 281PDF: 889 -
COVID-19 IN CHILDREN AND ADOLESCENT: CHARACTERISTICS AND SPECIFICITIES IN IMMUNOCOMPETENT AND ONCOHEMATOLOGICAL PATIENTS COVID-19 IN CHILDREN AND ADOLESCENT.
2533PDF: 947HTML: 306 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2241PDF: 977HTML: 1904 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4376PDF: 1723HTML: 1043 -
WALDENSTROM’S MACROGLOBULINEMIA: AN UPDATE
7660PDF: 2446HTML: 1740Table 1.: 214Table 2.: 224Table 3.: 208Table 4.: 209







